Off-the-shelf CD123 CAR-NK for R/R AML

This trial tests a new type of cell therapy called CAR-NK cells — specially engineered immune cells from a donor — to treat relapsed or treatment-resistant acute myeloid leukemia (AML), a type of blood cancer. The cells target a protein called CD123 found on leukemia cells. **You may be eligible if...** - You have AML that has come back after treatment or has not responded to at least 2 rounds of standard chemotherapy - Your leukemia cells test positive for the CD123 protein - You are 18 or older - Your liver, kidneys, and heart are functioning adequately - You are expected to live at least 3 months - You are willing to use effective contraception for at least 12 months after treatment **You may NOT be eligible if...** - Your leukemia has spread to the brain or spinal fluid - You have an active serious infection (including hepatitis B, hepatitis C, HIV, or tuberculosis) - You have used systemic steroids (by mouth or injection) in the last 4 weeks - You are pregnant or breastfeeding - You have a severe autoimmune disease or immune deficiency - You have a significant mental health condition or substance dependence Talk to your doctor to see if this trial is right for you.